Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
5.83
-0.03 (-0.51%)
Mar 13, 2025, 4:00 PM EST - Market closed
Kezar Life Sciences Revenue
In the year 2023, Kezar Life Sciences had annual revenue of $7.00M.
Revenue (ttm)
$7.00M
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
58
Market Cap
42.54M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
KZR News
- 23 days ago - Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025 - Business Wire
- 4 months ago - Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 4 months ago - Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire
- 4 months ago - Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - Business Wire
- 5 months ago - Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - Business Wire
- 5 months ago - Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - Business Wire
- 5 months ago - Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal - Business Wire
- 5 months ago - US FDA puts clinical hold on Kezar Life Sciences' lupus treatment trial - Reuters